TEMODAR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5260291 | MERCK SHARP DOHME | Tetrazine derivatives |
Aug, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5260291 (Pediatric) | MERCK SHARP DOHME | Tetrazine derivatives |
Feb, 2014
(10 years ago) | |
| US8623868 | MERCK SHARP DOHME | Processes of making and using pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(1 year, 2 months ago) | |
| US7786118 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(1 year, 2 months ago) | |
| US6987108 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same |
Sep, 2023
(7 months ago) | |
Temodar is owned by Merck Sharp Dohme.
Temodar contains Temozolomide.
Temodar has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Temodar are:
- US5260291*PED
- US8623868
- US7786118
- US6987108
- US5260291
Temodar was authorised for market use on 11 August, 1999.
Temodar is available in capsule;oral, powder;intravenous dosage forms.
Temodar can be used as treatment of malignant neoplasm.
The generics of Temodar are possible to be released after 08 September, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 15, 2012 |
Drugs and Companies using TEMOZOLOMIDE ingredient
Market Authorisation Date: 11 August, 1999
Treatment: Treatment of malignant neoplasm
Dosage: CAPSULE;ORAL; POWDER;INTRAVENOUS
How can I launch a generic of TEMODAR before it's drug patent expiration?
More Information on Dosage
TEMODAR family patents
